Christian Kellner

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: May 13, 2026

Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes.

Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 10, 2024

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT.

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT.

Journal: Blood
Published: April 04, 2024

Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy.

Prosaposin hyperglycosylation: a novel tumor immune escape mechanism and implications for cancer immunotherapy.

Journal: Signal transduction and targeted therapy
Published: March 20, 2024

Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.

Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.

Journal: Haematologica
Published: December 29, 2023

Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade.

Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade.

Journal: HemaSphere
Published: November 23, 2023

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.

Journal: Frontiers in immunology
Published: June 14, 2023

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.

Journal: Frontiers in immunology
Published: May 23, 2023

Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets.

Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets.

Journal: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
Published: January 18, 2023

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody.

Journal: Frontiers in immunology
Published: May 31, 2022

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.

Journal: Frontiers in immunology
Published: May 20, 2022

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.

Journal: Frontiers in immunology
Published: April 26, 2022
Showing 1-12 of 64

Last Updated: 09/26/2026